Linköping-based startup PredictMe has secured SEK 5 million (€450,000 / approximately $520,000) in seed funding to accelerate the development of its AI-powered epigenetic diagnostics platform. The investment was led by Swedish entrepreneur Linus Gunnarson, founder of Binogi and Chairman of Resolution Games.
The funding marks an important milestone for the Swedish HealthTech startup, which aims to transform healthcare by detecting diseases long before symptoms appear.
Turning Epigenetics into Actionable Healthcare
PredictMe was founded by Professor Maria Lerm and Professor Mika Gustafsson from Linköping University. Their research combines epigenetics—the study of how genes are regulated by environmental and lifestyle factors—with artificial intelligence to identify biological changes associated with disease.
Unlike DNA, which remains largely unchanged throughout life, epigenetic markers continuously reflect how the body responds to aging, infections, lifestyle, and disease. PredictMe’s platform analyzes these biological signals to help physicians identify patients at elevated risk before traditional symptoms emerge.
The company’s AI has been trained on data from approximately 150,000 individuals, processing nearly 60 billion biological data points, making it one of the world’s largest AI models focused on epigenetic analysis.
From Reactive to Preventive Medicine
Healthcare systems today often diagnose diseases only after symptoms become significant. PredictMe wants to shift that paradigm toward preventive and personalized medicine.
Its platform analyzes epigenetic markers from a simple blood sample and aims to deliver clinical decision support within 24 hours. Instead of replacing physicians, the system is designed to help prioritize patients who may require additional diagnostic testing.
This could prove particularly valuable for conditions where early detection dramatically improves outcomes while reducing healthcare costs.
PredictMe Delta Already on the Market
The company has already commercialized its first solution, PredictMe Delta, a blood test that estimates biological ageusing DNA methylation analysis combined with artificial intelligence.
Unlike chronological age, biological age reflects an individual’s physiological condition. Two people of the same age may have significantly different biological health profiles, information that can influence treatment decisions in areas such as oncology, surgery, and organ transplantation.
As precision medicine continues to evolve, biomarkers like biological age are becoming increasingly relevant for personalized healthcare.
New Capital to Accelerate Growth
The newly raised capital will support continued development of PredictMe’s AI platform and expand its commercial activities.
The seed round follows SEK 8 million in previous research funding from the Knut and Alice Wallenberg Foundation and Sweden’s innovation agency Vinnova, demonstrating strong institutional confidence in the company’s scientific foundation.
Investor Linus Gunnarson believes the convergence of artificial intelligence and epigenetics represents one of the most promising directions for future healthcare.
Sweden Continues to Lead HealthTech Innovation
PredictMe reflects Sweden’s growing strength in AI-driven life sciences, where university research increasingly translates into commercial innovation.
By combining world-class expertise in epigenetics with explainable AI, the company is building tools that could help healthcare systems move from treating diseases after they occur to identifying risks much earlier.
As populations age and demand for preventive medicine grows, platforms capable of delivering rapid, data-driven health insights may become an essential part of modern clinical practice.
With fresh funding secured and its first commercial product already available, PredictMe is positioning itself among Sweden’s most promising emerging HealthTech startups.
